9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference
RALEIGH, NC / ACCESSWIRE / March 21, 2022 - 9 Meters Biopharma (NASDAQ:NMTR) announced that its CEO, John Temperato, will present at the Maxim Group 2022 Virtual Growth Conference on March 28-30, 2022. The presentation will highlight the company's advanced pipeline, focusing on vurolenatide, a Phase 2 drug for short bowel syndrome, and larazotide, a Phase 3 treatment for celiac disease. Important data for both drugs is expected soon. For further details, visit www.9meters.com.
- None.
- None.
RALEIGH, NC / ACCESSWIRE / March 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the Maxim Group 2022 Virtual Growth Conference hosted by M-Vest on March 28 - 30, 2022.
Maxim Group 2022 Virtual Growth Conference
Presentation: Available for viewing on March 28 - 30, 2022
Webcast: https://m-vest.com/events/2022-virtual-growth-conference/p/nmtr
The presentation will also be available in the events section of the 9 Meters website.
The presentation will highlight the Company's advanced pipeline and upcoming clinical milestones for vurolenatide, its long-acting GLP-1 agonist for short bowel syndrome, currently in a Phase 2 clinical study with data anticipated in the second quarter of 2022, and larazotide, its Phase 3 tight junction regulator for celiac disease, with an interim analysis anticipated in early June 2022.
About 9 Meters Biopharma
9 Meters Biopharma, Inc. is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, GI conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The Company is advancing vurolenatide, a proprietary Phase 2 long-acting GLP-1 agonist, for short bowel syndrome (SBS); larazotide, a Phase 3 tight junction regulator in non-responsive celiac disease; and several near clinical-stage assets.
For more information please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.
Forward-Looking Statements
This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, anticipated milestones and any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: reliance on research and development partners; uncertainties associated with the clinical development and regulatory approval of product candidates; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; the impact of COVID-19 on our operations, enrollment in and timing of clinical trials; intellectual property risks; risks related to the inability of the Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; reliance on collaborators; and risks associated with acquiring and developing additional compounds. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, Form 10-Q for the quarter ended September 30, 2021, and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Corporate Contact
Al Medwar
SVP, Investor Relations & Corporate Communications
9 Meters Biopharma, Inc.
investor-relations@9meters.com
Media Contact
Veronica Eames
LifeSci Communications, LLC
veames@lifescicomms.com
203-942-4626
SOURCE: 9 Meters Biopharma, Inc.
View source version on accesswire.com:
https://www.accesswire.com/693798/9-Meters-Biopharma-to-Present-at-the-Maxim-Group-2022-Virtual-Growth-Conference
FAQ
What is the date of the Maxim Group 2022 Virtual Growth Conference for 9 Meters Biopharma?
Who will present at the Maxim Group conference for NMTR?
What products will 9 Meters Biopharma discuss at the conference?
When is the data for vurolenatide expected?
When is the interim analysis for larazotide expected?
